Effects of canrenone in patients with metabolic syndrome

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2161-2169

  Derosa, Giuseppe ^a   Bonaventura, Aldo ^a   Bianchi, Lucio ^a   Romano, Davide ^a   D'Angelo, Angela ^a   Fogari, Elena ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aldosterone; Brain natriuretic peptide; Canrenone; Inflammation; Metabolic syndrome

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANRENONE; CREATININE; GLUCOSE; INSULIN; LIPID; PLACEBO; POTASSIUM; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; ALDOSTERONE; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CANRENONE; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885676827     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.832756     Document Type: Article

References (45)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-9 (Pubitemid 34251969)
2. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421
4. de Simone G, Olsen MH, Wachtell K, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007;21(8):625-32 (Pubitemid 47162725)
5. de Simone G, Devereux RB, Chinali M, et al. Strong Heart Study Investigators. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007;30:1851-6 (Pubitemid 47036363)
6. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 2007;17(6):473-81 (Pubitemid 47082427)
7. Caprio M, Fève B, Claës A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185-94 (Pubitemid 47026453)
8. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004;13(4):451-8 (Pubitemid 38901625)
9. Stewart P. The adrenal cortex. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 11th edition. Saunders Elsevier. Philadelphia: 2008. p. 445-504
10. Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE. The ubiquitous mineralocorticoid receptor: clinicalimplications. Curr Hypertens Rep 2012;14(6):573-80
11. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000;61(1):52-60 (Pubitemid 30246169)
12. Goodman and Gilman's. The pharmacological basis of therapeutics. McGraw-Hill Companies, Inc., New York, NY, 2006
13. de Simone G, Chinali M, Mureddu GF, et al. AREA-in-CHF Investigators. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutr Metab Cardiovasc Dis 2011;21(10):783-91
14. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91 (Pubitemid 44465710)
15. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
16. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19 (Pubitemid 15018832)
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95 (Pubitemid 38680001)
19. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30 (Pubitemid 8061822)
20. Wahlefeld AW. Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis. 2nd English edition. Academic Press, Inc. New York: 1974. p. 18-31
21. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
23. Boccanelli A, Cacciatore G, Mureddu GF, et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). J Cardiovasc Med (Hagerstown) 2007;8(9):683-91 (Pubitemid 47282047)
24. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45(12):2136-41
25. Zhang M, Tracey K. The cytokine handbook. 3rd edition. Academic Press. San Diego: 1988
26. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2011;34:S4-S61
27. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:214-23
28. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317(6):350-7 (Pubitemid 17118813)
29. Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill New York: 1971
30. Cicero AF, Derosa G, Bove M, et al. Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2009;16(6):698-704
31. Fogari R, Zoppi A, Mugellini A, et al. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res 2011;34(12):1321-6
32. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007;32(3):261-8 (Pubitemid 46699517)
33. Fogari R, Zoppi A, Mugellini A, et al. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010;42(12):892-6
34. Hu LJ, Deng SB, Du JL, et al. Additional use of an aldosterone antagonist in patients with mild-to-moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;75(5):1202-12
35. Penfornis P, Viengchareun S, Le Menuet D, et al. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab 2000;279(2):E386-94
36. Viengchareun S, Penfornis P, Zennaro MC, Lombès M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001;280(4):E640-9
37. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003;100(24):14211-16 (Pubitemid 37499216)
38. Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59(5):1069-78
39. Kraus D, Jäger J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005;37(7):455-9 (Pubitemid 41081228)
40. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-14 (Pubitemid 27446179)
41. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91 (Pubitemid 23036092)
42. Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5 (Pubitemid 29278870)
43. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-7
44. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012;350(2):256-65
45. de Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012;28(6):706-11